Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC4100 | PCI 29732 |
| Potent BTK inhibitor (IC50 = 0.3 nM). Blocks B cell antigen receptor (BCR)-mediated gene expression in CD20+ B cells. | |
| BCC4112 | Sumanirole maleate |
| High affinity D2 receptor agonist (EC50 values are between 17 and 75 nM in cell-based assays). Displays >200-fold selectivity for the D2 receptor against other dopamine receptor subtypes (Ki values are 9.0, 1940, >2190 and >7140 for D2, D3, D4 and D1 receptors respectively). Exhibits antiParkinsonian activity similar to ropinirole. | |
| BCC4146 | Xanomeline oxalate |
| Functionally selective muscarinic M1 receptor agonist (EC50 values are 0.3, 5, 42, 52 and 92.5 nM at M1, M3, M5, M4 and M2 receptors respectively). Displays a complex pharmacological profile: reversible and wash-resistant binding, resulting in full agonist activity at M1; delayed wash-resistant partial agonist activity at M2; and delayed wash-resistant full agonist activity at M4. Exhibits antipsychotic activity, and improves cognitive deficits and behavioral disturbances in Alzheimer's disease and schizophrenia. | |
| BCC4161 | MCOPPB trihydrochloride |
| High affinity NOP receptor agonist (pKi = 10.07 for the human NOP receptor). Exhibits anxiolytic effects with no effect on memory or locomotion. Regarded as one of the most potent, non-peptide NOP full agonists in vitro. | |
| BCC4179 | GSK 2830371 |
| Potent and selective allosteric inhibitor of Wip1 phosphatase (IC50 = 6 nM). Exhibits selectivity for Wip1 over 21 other phosphatases. Increases phosphorylation of Wip1 substrates, including p53, Chk2, H2AX and ATM. Attenuates tumor cell growth in a variety of lymphoid cell lines. Also inhibits lymphoma xenograft growth in vivo. Potentiates growth inhibitory effects of MDM2 inhibition in cancer cell lines in a p53-dependent manner. Orally bioavailable. | |
| BCC4199 | TRPC6 inhibitor |
| Potent TRPC6 inhibitor (IC50 values are 9.5, 226 and 282 nM for TRPC6, TRPC7 and TRPC3-mediated Ca2+ influx). Exhibits no significant activity at TRPC4 and TRPC5 channels. Suppresses TRPC6-dependent acute hypoxic pulmonary vasoconstriction (HPV) in the isolated perfused mouse lung. Orally bioavailable. | |
| BCC4207 | Cisapride |
| 5-HT4 receptor agonist and gastrokinetic agent. Stimulates intestinal acetylcholine release, possibly via 5-HT4 receptor-dependent and -independent mechanisms, leading to increased intestinal motility. | |
| BCC4219 | Aniracetam |
| Nootropic, with modulatory actions through allosteric potentiation of AMPA specific receptors, reduction of glutamate receptor desensitization and potentiation of metabotropic glutamate receptor activity. Anxiolytic following systemic administration. | |
